Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591535 | 0.93 | THRB (0.58) | TSHRTHRBALDH1A1TDP1MEN1 | |
| SCHEMBL2219398 | 0.92 | TSHR (0.52) | TSHRTHRBALDH1A1TDP1CHRM2 | |
| SCHEMBL10893401 | 0.91 | THRB (0.56) | TSHRTHRBALDH1A1TDP1MEN1 | |
| SCHEMBL4063408 | 0.91 | TDP1 (0.50) | TSHRTHRBALDH1A1TDP1HSD17B10 | |
| SCHEMBL27707717 | 0.91 | TSHR (0.44) | TSHRTHRBALDH1A1TDP1 | |
| SCHEMBL5984326 | 0.91 | TSHR (0.44) | TSHRTHRBALDH1A1TDP1MEN1 | |
| SCHEMBL17109947 | 0.88 | TSHR (0.40) | TSHRTHRBALDH1A1TDP1MEN1 | |
| SCHEMBL12804553 | 0.88 | TSHR (0.40) | TSHRTHRBALDH1A1TDP1 | |
| SCHEMBL26786230 | 0.88 | TSHR (0.56) | TSHRTHRBALDH1A1TDP1 | |
| SCHEMBL7191777 | 0.88 | TSHR (0.46) | TSHRTHRBALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108119-A1 | ARCHITECTURED POLYMERS AND RELATED METHODS | AVERY DENNISON CORPORATION (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024108119-A1 | ARCHITECTURED POLYMERS AND RELATED METHODS | AVERY DENNISON CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| US-8592542-B2 | Porous resin beads and method of producing nucleic acid using the same | NITTO DENKO CORPORATION (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2138519-B1 | Porous resin beads and method of producing nucleic acid using the same | NITTO DENKO CORP (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20090326210-A1 | POROUS RESIN BEADS AND METHOD OF PRODUCING NUCLEIC ACID USING THE SAME | NITTO DENKO CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2138519-A1 | Porous resin beads and method of producing nucleic acid using the same | Nitto Denko Corporation (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326210-A1 | POROUS RESIN BEADS AND METHOD OF PRODUCING NUCLEIC ACID USING THE SAME | PCNA, ARID2, PHAX | TSHR 4117/4885THRB 3783/4885ALDH1A1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.